G1 Therapeutics (GTHX) Set to Announce Earnings on Thursday

G1 Therapeutics (NASDAQ:GTHX) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect G1 Therapeutics to post earnings of ($0.17) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

G1 Therapeutics Stock Performance

Shares of NASDAQ GTHX opened at $4.25 on Wednesday. The company’s fifty day moving average price is $3.10 and its 200 day moving average price is $3.63. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $6.14. The company has a market capitalization of $222.19 million, a PE ratio of -6.85 and a beta of 1.53. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.55 and a current ratio of 2.94.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $3.00 price target (down from $5.00) on shares of G1 Therapeutics in a report on Monday, June 24th. HC Wainwright decreased their price objective on shares of G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, June 25th. Finally, Needham & Company LLC decreased their price objective on shares of G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, June 25th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.